Astellas Pharma (OTCMKTS:ALPMY) Sees Strong Trading Volume – Should You Buy?

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw an uptick in trading volume on Tuesday . Approximately 112,791 shares changed hands during mid-day trading, a decline of 33% from the previous session’s volume of 168,276 shares.The stock last traded at $13.58 and had previously closed at $13.25.

Analysts Set New Price Targets

A number of brokerages have issued reports on ALPMY. Jefferies Financial Group upgraded Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 24th. Zacks Research upgraded Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, June 23rd. Two research analysts have rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, Astellas Pharma presently has an average rating of “Moderate Buy”.

Astellas Pharma Trading Up 2.5%

The company’s fifty day simple moving average is $13.61 and its 200-day simple moving average is $14.64. The firm has a market capitalization of $24.58 billion, a PE ratio of 12.65 and a beta of 0.07. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.17 and a quick ratio of 0.90.

Astellas Pharma (OTCMKTS:ALPMY) last released its earnings results on Monday, April 27th. The company reported $0.33 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.14. Astellas Pharma had a net margin of 13.66% and a return on equity of 23.54%. The business had revenue of $3.38 billion during the quarter, compared to analysts’ expectations of $3.28 billion. As a group, sell-side analysts expect that Astellas Pharma Inc. will post 1.25 earnings per share for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).